P/OSPeptideOS evidence & status map
OPEN SOURCE MEDICINE FOUNDATIONLast reviewed 2026-10-10No dosing · no vendors · no advicesource file

← All compounds · evidence tier first, by design

Evidence tier for each claimed use · ← established · unknown →
UseE1E2E3E4E5E6E7E8
E1 Weight reduction in obesity or overweightE1
E2 Liver fat in obesity with metabolic dysfunction-associated steatotic liver disease (MASLD)E2
E3 Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosisE3
Class B · Investigational

Survodutide

Synthetic lipidated peptide; full structure not verified for this record.

Non-standard residues or modifications: no plain one-letter sequence

Codes: BI 456906 · CAS 2805997-46-8

An investigational synthetic peptide from Boehringer Ingelheim that activates the glucagon and GLP-1 receptors. It is in phase 3 development for obesity and for metabolic dysfunction-associated steatotic liver disease, including steatohepatitis with fibrosis or cirrhosis. It is not approved in any jurisdiction checked.

  • US B investigational
  • EU B investigational
  • UK B investigational
  • CA B investigational
  • AU B investigational
  • JP B investigational
  • CN B investigational

01Regulatory status, by jurisdiction

Standing notice. This compound is an investigational drug. It is not approved in any jurisdiction. There is no lawful supply. Any material sold under this name is of unverified origin, and is neither manufactured nor tested to pharmaceutical standards.
JurisdictionStatusDetail and primary source
USInvestigationalNo Drugs@FDA application found for survodutide (openFDA Drugs@FDA query by active ingredient returns no records). Phase 3 trials sponsored by Boehringer Ingelheim are registered on ClinicalTrials.gov.
“"code": "NOT_FOUND", "message": "No matches found!"”
openFDA Drugs@FDA API query: active ingredient survodutide · retrieved 2026-10-10
EUInvestigationalSurvodutide does not appear in the EMA medicines dataset (2,748 records of centrally processed medicines, timestamp 2026-10-10).
“"total_records": 2748, "timestamp": "2026-10-10T06:02:36Z"”
EMA medicines data (JSON report) · retrieved 2026-10-10
CAInvestigationalHealth Canada Drug Product Database active-ingredient query for survodutide returns an empty result.
“[]”
Health Canada Drug Product Database API: active ingredient survodutide · retrieved 2026-10-10
AUInvestigationalTGA Product Information repository search for survodutide returns no documents.
“Search PI Trade Names and Active Ingredients containing survodutide . 0 Documents available.”
TGA eBS - Product and Consumer Medicine Information (search: survodutide) · retrieved 2026-10-10
JPInvestigationalSurvodutide does not appear in the PMDA List of Approved Products (New Drugs), which covers approvals through February 2026; later approvals would not be shown. A Japanese phase 3 trial (NCT06176365) is completed.
“April 2004 to February 2026”
PMDA List of Approved Products: New Drugs (April 2004 to February 2026) · retrieved 2026-10-10
UK CNNot yet verified from a primary source. No status is shown rather than an unsourced one.

Sport (WADA): Prohibited · class S0. “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development” WADA source

02What the human evidence shows

E1

Weight reduction in obesity or overweight

n/cpublished human RCTs
n/cpublished human trials
20registered studies
1with posted results

n/c: not counted here; see the cited review.

Two published phase 3 trials and one phase 2 trial. SYNCHRONIZE-1 (725 adults without diabetes, 76 weeks): weight change -12.2% and -13.0% in the two dose groups versus -5.4% with placebo. SYNCHRONIZE-2 (752 adults with type 2 diabetes, 76 weeks): -8.2% and -9.8% versus -3.9%. The phase 2 trial (387 adults, 46 weeks) reported -6.2% to -14.9% versus -2.8%, with only 60% completing treatment.

  • [1] SYNCHRONIZE-1: weight change -12.2% and -13.0% vs -5.4% with placebo at 76 weeks
  • [2] SYNCHRONIZE-2: weight change -8.2% and -9.8% vs -3.9% with placebo at 76 weeks in obesity with type 2 diabetes
  • [3] Phase 2: weight change -6.2% to -14.9% vs -2.8% with placebo at 46 weeks

Registered-study counts: ClinicalTrials.gov intervention search “survodutide AND obesity”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E2

Liver fat in obesity with metabolic dysfunction-associated steatotic liver disease (MASLD)

n/cpublished human RCTs
n/cpublished human trials
6registered studies
0with posted results

n/c: not counted here; see the cited review.

One phase 3 trial (SYNCHRONIZE-MASLD, 216 adults, 48 weeks). A reduction of at least 30% in MRI-measured liver fat occurred in 68.5% with survodutide versus 28.6% with placebo (treatment-regimen estimand). Liver fat is an imaging surrogate; the authors note short duration and recruitment limited to the US and Spain.

  • [4] At least 30% liver-fat reduction in 68.5% vs 28.6% with placebo at 48 weeks (treatment-regimen estimand)

Registered-study counts: ClinicalTrials.gov intervention search “survodutide AND liver”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

E3

Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis

n/cpublished human RCTs
n/cpublished human trials
5registered studies
1with posted results

n/c: not counted here; see the cited review.

One phase 2 biopsy trial (293 treated participants, 48 weeks). MASH improvement without worsening fibrosis occurred in 43% to 62% across dose groups versus 14% with placebo; fibrosis improvement by at least one stage in 34% to 36% versus 22%. Phase 3 histology and outcome trials (LIVERAGE, LIVERAGE-Cirrhosis) are recruiting.

  • [5] MASH improvement without fibrosis worsening 43-62% vs 14% with placebo (phase 2)

Registered-study counts: ClinicalTrials.gov intervention search “survodutide AND steatohepatitis”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.

Key registered trials

NCTTitle (as registered)PhaseStatus
NCT06066515A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight3Completed
NCT06066528A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight3Completed
NCT06077864A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)3Completed
NCT06309992A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)3Completed
NCT06176365A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease3Completed
NCT06214741A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight3Completed
NCT06632444LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis3Recruiting
NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis3Recruiting
NCT04771273A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)2Completed
NCT04667377A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight2Completed

03Safety signals

S2Substantial controlled-trial safety data

There are no adequate human safety data. The absence of reported harm is not evidence of safety.

  • Gastrointestinal adverse events [1]
    In SYNCHRONIZE-1, gastrointestinal adverse events occurred in 80.9% and 89.7% of the two survodutide groups versus 47.9% with placebo.
  • High treatment discontinuation in dose-finding [3]
    In the phase 2 obesity trial, 61% of survodutide recipients completed the 46-week treatment period (60% on placebo); gastrointestinal adverse events occurred in 75% versus 42%.

04What is unknown

  • Cardiovascular safety result: SYNCHRONIZE-CVOT (NCT06077864) is completed on ClinicalTrials.gov but no publication was located as of 2026-10-10
  • Whether liver-fat and histology improvements translate into fewer cirrhosis or liver-related events; LIVERAGE trials are recruiting
  • Safety beyond 76 weeks of exposure, the longest duration in published phase 3 trials
  • Effects of glucagon receptor agonism on heart rate, lean mass and amino-acid metabolism over the long term in humans
  • Identity and purity of any material sold outside trials; no lawful supply exists and no assay data were located

05Product quality

No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.

06Citations

  1. Survodutide Once Weekly for the Treatment of Adults with Obesity (2026). doi:10.1056/nejmoa2600751
  2. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (2026). doi:10.1056/nejmoa2607219
  3. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024). doi:10.1016/S2213-8587(23)00356-X
  4. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026). doi:10.1038/s41591-026-04479-3
  5. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024). doi:10.1056/NEJMoa2401755

Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.

07Mechanism

Survodutide is a peptide agonist of both the glucagon receptor and the GLP-1 receptor.

Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.

Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.